{"prompt": "['Clinical Study Protocol', 'R2810-ONC-1676 Amendment 7', 'Amendment 1', 'The following table outlines the changes made to the protocol and the affected sections.', 'Change', 'Sections Changed', 'An exclusion criterion has been added for the', 'Section 6.2.2 Exclusion Criteria #18', 'following reason: Patients who have', 'previously been treated with idelalisib will be', 'excluded from treatment with REGN2810 as', 'a result of the safety findings for 3 patients', 'with indolent lymphoma previously treated', 'with idelalisib, a phosphatidylinositol', '3-kinase (PI 3-K) inhibitor, in study', 'R1979-ONC-1504. Following a single dose', 'of REGN2810 monotherapy in each case,', '2 patients experienced severe stomatitis', 'and/or skin reactions. The third patient', 'experienced myositis and myasthenia gravis', 'after 2 doses of REGN2810.', 'Additional safety guidance language added', 'Section 8.5.1 Study Drug Discontinuation', 'for the management of patients developing', 'stomatitis or mucositis', 'An adverse event of special interest (AESI)', 'Section 9.4.3 Other Events that Require', 'has been added to the list of AESIs:', 'Accelerated Reporting to Sponsor', 'An irAE of any grade in a patient previously', 'treated with a PI 3-K inhibitor.', 'Regeneron Pharmaceuticals, Inc.', 'Page 19 of 145', 'CONFIDENTIAL', 'VV-RIM-00146791-1.0 Approved - 14 Apr 2021 GMT-5:00']['Clinical Study Protocol', 'R2810-ONC-1676 Amendment 7', 'TABLE OF CONTENTS', 'AMENDMENT HISTORY', '3', 'CLINICAL STUDY PROTOCOL SYNOPSIS', '27', 'LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS', '32', '1.', 'INTRODUCTION', '35', '2.', 'STUDY OBJECTIVES', '37', '2.1.', 'Primary Objective', '37', '2.2.', 'Secondary Objectives', '37', '2.3.', 'Exploratory Objectives', '38', '3.', 'HYPOTHESIS AND RATIONALE', '38', '3.1.', 'Hypothesis', '38', '3.2.', 'Rationale', '38', '3.2.1.', 'Rationale for Patient Population and Study Design', '38', '3.2.2.', 'Rationale for Cemiplimab Dose Selection', '40', '3.2.3.', \"Rationale for Investigator's Choice Chemotherapy Options\", '40', '4.', 'STUDY VARIABLES', '43', '4.1.', 'Demographic and Baseline Characteristics', '43', '4.2.', 'Primary and Secondary Endpoints', '43', '4.2.1.', 'Primary Endpoint', '43', '4.2.2.', 'Secondary Endpoints', '43', '4.2.3.', 'Other Secondary Endpoints', '43', '4.3.', 'Exploratory Endpoints', '44', '4.3.1.', 'Pharmacokinetic Variables', '44', '4.3.2.', 'Anti-Drug Antibody Variables', '44', '4.3.3.', 'Other Exploratory Variables', '44', '5.', 'STUDY DESIGN', '44', '5.1.', 'Study Description and Duration', '44', '5.1.1.', 'End of Treatment Definition', '46', '5.1.2.', 'End of Study Definition', '46', '5.2.', 'Planned Interim Analysis', '46', '5.3.', 'Study Committees', '46', '5.3.1.', 'Independent Data Monitoring Committee', '46', 'Regeneron Pharmaceuticals, Inc.', 'Page 20 of 145', 'CONFIDENTIAL', 'VV-RIM-00146791-1.( Approved - 14 Apr 2021 GMT-5:00']['Clinical Study Protocol', 'R2810-ONC-1676 Amendment 7', '5.3.2.', 'Trial Steering Committee', '47', '5.4.', 'Study Conduct in Response to COVID-19', '47', '6.', 'SELECTION, WITHDRAWAL, AND REPLACEMENT OF PATIENTS', '47', '6.1.', 'Number of Patients Planned', '47', '6.2.', 'Study Population', '47', '6.2.1.', 'Inclusion Criteria', '47', '6.2.2.', 'Exclusion Criteria', '49', '6.3.', 'Premature Withdrawal from the Study', '51', '6.4.', 'Replacement of Patients', '52', '7.', 'STUDY SCHEDULE OF EVENTS AND PROCEDURES', '52', '7.1.', 'Schedule of Events', '52', '7.1.1.', 'COVID-19 Adaptation', '52', '7.1.2.', 'Footnotes for the Schedule of Events Table for Screening and Treatment', '55', '7.1.3.', 'Unscheduled Visits', '56', '7.1.4.', 'Post-Treatment Follow-Up', '56', '7.1.5.', 'Footnotes for the Schedule of Events Table for Post-Treatment Follow-up', '56', '7.1.6.', 'Option for Retreatment', '57', '7.1.7.', 'Note Regarding IDMC Interim Analysis 2', '58', '7.1.7.1.', 'Cemiplimab Extension Phase of the Study', '58', '7.1.7.2.', 'Footnotes for the Schedule of Events Table 3 for the Cemiplimab Extension', 'Phase', '60', '7.2.', 'Study Procedures', '60', '7.2.1.', 'Procedures Performed at the Screening Visit', '60', '7.2.2.', 'Efficacy Procedures', '61', '7.2.3.', 'Survival Data Collection', '61', '7.2.4.', 'Quality of Life Questionnaires', '61', '7.2.5.', 'Safety Procedures', '62', '7.2.5.1.', 'Vital Signs', '62', '7.2.5.2.', 'Physical Examination', '62', '7.2.5.3.', 'Electrocardiogram', '62', '7.2.5.4.', 'Laboratory Testing', '63', '7.2.5.5.', 'Anti-Drug Antibody Measurements and Samples', '64', '7.2.5.6.', 'Pharmacokinetic Samples', '64', 'Regeneron Pharmaceuticals, Inc.', 'Page 21 of 145', 'CONFIDENTIAL', 'VV-RIM-00146791-1.( Approved - 14 Apr 2021 GMT-5:00']\n\n###\n\n", "completion": "END"}